{"product_id":"imcr-pestle-analysis","title":"(IMCR) Immunocore Holdings plc PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Immunocore Holdings plc PESTLE Analysis helps you map political, economic, social, technological, legal, and environmental forces shaping the company’s outlook. The page includes a real preview of the report so you can review style and depth before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUK-US regulatory exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore is based in Abingdon, UK, and sells KIMMTRAK in the US and Europe, so it depends on UK, US, and EU biotech rules at the same time. That matters because a single policy change can shift clinical trial approvals, export controls, GMP checks, and launch timing across 3 regulators: MHRA, FDA, and EMA. Any weaker UK-US coordination can slow site clearances and raise cross-border compliance cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic funding for life sciences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic funding matters for Immunocore Holdings plc because biotech R\u0026amp;D often leans on grants, tax credits, and translational awards to de-risk early work. Its oncology, infectious disease, and autoimmune pipeline fits areas backed by programs like Horizon Europe, which has a €95.5 billion budget for 2021-27. If that support weakens, Immunocore would face higher cash burn and a costlier path to proof-of-concept.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and reimbursement politics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKIMMTRAK's uptake hinges on payer and hospital coverage, so launch speed is tied to reimbursement politics more than to approval alone.\u003c\/p\u003e\n\u003cp\u003eFor rare-disease and oncology drugs, national buyers keep pricing scrutiny high; premium launch prices can slow formulary access and prior-auth reviews.\u003c\/p\u003e\n\u003cp\u003eAny delay in coverage can cap sales in the first 12-24 months after launch, even when the drug is already approved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeopolitical supply-chain risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces geopolitically exposed biologics supply chains because key inputs, specialty reagents, and 2-8°C transport can cross multiple borders before a dose reaches patients. Trade friction, sanctions, or customs delays can slow clinical supply and US launch inventory, where even a 1-2 week delay can strain trial dosing and release schedules.\u003c\/p\u003e\n\u003cp\u003eThat risk is sharper for a company running international studies and a US-facing commercial plan, since disruption can hit both development timelines and revenue conversion at once. In 2025, the World Trade Organization still flagged uneven trade conditions and shipping frictions as a drag on cross-border flows, which matters for temperature-sensitive medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal sourcing raises single-point failure risk\u003c\/li\u003e\n\u003cli\u003eCold chain delays can spoil biologics\u003c\/li\u003e\n\u003cli\u003eBorder frictions hit trials and US sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare policy volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare policy volatility matters for Immunocore Holdings plc because cancer access depends on shifting national budgets, reimbursement rules, and drug-spending caps. With one marketed product, KIMMTRAK, and a multi-year pipeline, any delay in formulary placement or prior-approval rules can slow patient starts and push revenue timing.\u003c\/p\u003e\n\u003cp\u003ePolicy changes can also tighten hospital purchasing and widen access gaps across markets, even when a therapy is approved. That risk is sharper for a small oncology company: one access setback can affect a large share of near-term sales and trial-to-commercial planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBudget pressure can slow access.\u003c\/li\u003e\n\u003cli\u003eFormulary shifts can delay starts.\u003c\/li\u003e\n\u003cli\u003eOne product raises concentration risk.\u003c\/li\u003e\n\u003cli\u003ePipeline timing depends on policy stability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore Faces Triple-Regulator and Reimbursement Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces political risk from three rule sets at once: UK MHRA, US FDA, and EU EMA. For R\u0026amp;D, public support still matters; Horizon Europe keeps €95.5bn for 2021-27, but any cut would lift cash burn. Reimbursement politics can also slow KIMMTRAK access even after approval.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon Europe\u003c\/td\u003e\n\u003ctd\u003e€95.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eMHRA, FDA, EMA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket risk\u003c\/td\u003e\n\u003ctd\u003eCoverage delays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps the key political, economic, social, technological, environmental, and legal forces shaping Immunocore Holdings plc’s market outlook and strategic risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Immunocore Holdings plc PESTLE snapshot that simplifies external risk review for faster, clearer strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary industry reports, clinical data, regulatory filings, and market benchmarks to speed due diligence and validate key assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-product revenue base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s marketed revenue still leans on KIMMTRAK, so cash flow depends on demand in unresectable or metastatic uveal melanoma. In 2024, KIMMTRAK net product sales were about $265 million, showing how concentrated the base remains. That leaves the business exposed if uptake slows before new pipeline assets reach market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D expenditure profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc is still funding multiple Phase I\/II programs and preclinical assets, so R\u0026amp;D stays the main cost driver. Early trials need cash for patient enrollment, GMP manufacturing, and regulatory work, and those costs rise before any product revenue arrives. That is why profitability can stay under pressure for years while the pipeline advances.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc reports in GBP, but its US commercial base means GBP\/USD risk is real, and sales in Europe and other markets add more FX noise. In 2025, sterling moved sharply against the dollar, so even modest swings can change reported revenue and make operating-cost planning harder. That can hit margin forecasts, especially when research, staff, and suppliers are paid in mixed currencies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital-market dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc still depends on capital markets because biotech R\u0026amp;D is cash-heavy and long-dated; the company had 1 commercial product, KIMMTRAK, and multiple pipeline programs to fund in 2025. When biotech sentiment weakens, equity raises can get pricier and more dilutive, so access to partnerships and milestone cash matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePipeline breadth raises funding needs.\u003c\/li\u003e\n\u003cli\u003eMarket dips can lift dilution risk.\u003c\/li\u003e\n\u003cli\u003ePartnership cash can ease funding gaps.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease pricing economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKIMMTRAK’s economics depend on a tiny eligible pool: uveal melanoma incidence is about 5-6 cases per 1 million people a year, so Immunocore Holdings plc needs premium rare-disease pricing to recover R\u0026amp;D and launch costs. That pricing power is real, but payers still review coverage tightly, so uptake hinges on proving durable survival benefit and keeping access in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall pool, high price pressure\u003c\/li\u003e\n\u003cli\u003ePayer review can slow uptake\u003c\/li\u003e\n\u003cli\u003eCoverage persistence drives revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore’s KIMMTRAK Dependence Keeps Growth and Funding in Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s economics still hinge on one drug: KIMMTRAK, which delivered about $265 million in net product sales in 2024, so revenue concentration remains high. Uveal melanoma stays a tiny market at roughly 5-6 cases per 1 million people a year, so pricing must stay premium to fund R\u0026amp;D. Cash need stays heavy while multiple Phase I\/II programs move forward.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKIMMTRAK net sales\u003c\/td\u003e\n\u003ctd\u003e~$265 million (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUveal melanoma incidence\u003c\/td\u003e\n\u003ctd\u003e~5-6 per 1 million\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial products\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFX risk also matters because Immunocore Holdings plc reports in GBP but sells mainly in the US, so GBP\/USD moves can swing reported revenue and costs. Biotech funding is still market-linked, so weak sentiment can raise dilution risk and make partnerships more important.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eImmunocore Holdings plc PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Immunocore Holdings plc PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eThis snapshot reflects the real file you’re buying: no placeholders, no teasers—just the complete strategic assessment of political, economic, social, technological, legal, and environmental factors.\u003c\/p\u003e\n\u003cp\u003eAfter checkout you’ll instantly download this same document—clear insights, actionable risks and opportunities, and ready-to-present sections for your analysis or board review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh unmet need in cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc targets high-unmet-need cancers like uveal melanoma, which affects about 3,000 patients a year in the US and often spreads in about 50% of cases. Once metastatic, 5-year survival is often below 20%, so patients and clinicians actively seek new options after standard therapy fails. That urgency supports demand for differentiated immunotherapies in solid tumors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall patient population in uveal melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUveal melanoma is rare, at roughly 5 to 6 cases per million people a year, so the commercial pool for KIMMTRAK stays small. In the U.S., that is only about 1,700 to 2,000 new cases annually, even though the disease drives real unmet need. Small numbers can lift specialist awareness fast, but diagnosis delays and referral pathways still shape access and total demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreference for targeted therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and physicians increasingly favor precise treatments over broad chemotherapy, especially in cancers with limited options. Immunocore’s tebentafusp is a targeted T-cell engager and is still the only approved therapy for HLA-A*02:01-positive metastatic uveal melanoma, where 1-year survival in phase 3 was 73% vs 59% with investigator’s choice. Adoption rises when clinicians see clear benefit and manageable toxicity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChronic disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChronic disease burden supports demand for Immunocore Holdings plc's pipeline in chronic hepatitis B, HIV, and autoimmune disease. WHO estimates 254 million people live with hepatitis B and 39 million with HIV, while autoimmune diseases affect about 5%-10% of people worldwide. These long-term illnesses need sustained care, so therapies that cut lifelong treatment burden have strong social pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e254 million hepatitis B cases\u003c\/li\u003e\n\u003cli\u003e39 million people with HIV\u003c\/li\u003e\n\u003cli\u003e5%-10% global autoimmune burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient trust and specialist referral\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc depends on specialist referrals because immunotherapy use usually starts in oncology centers, not primary care. Uptake rises when clinicians and patient groups trust the safety, efficacy, and real-world results of a treatment. For rare cancers, that trust can matter as much as the label.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReferrals drive first access.\u003c\/li\u003e\n\u003cli\u003eAwareness lifts adoption.\u003c\/li\u003e\n\u003cli\u003eTrust shapes treatment choice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Cancer, Real Data: Why Immunocore’s Uptake Can Move Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc serves rare-disease oncology markets, so diagnosis speed, specialist referral, and patient advocacy strongly shape uptake. Uveal melanoma is about 5–6 per million a year, or roughly 1,700–2,000 U.S. cases, so even small shifts in awareness can move demand. Trust in real-world safety and survival data matters most.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUveal melanoma incidence\u003c\/td\u003e\n\u003ctd\u003e5–6\/million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cases\u003c\/td\u003e\n\u003ctd\u003e1,700–2,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetastatic 5-year survival\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 1-year survival\u003c\/td\u003e\n\u003ctd\u003e73% vs 59%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTCR-based immunotherapy platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s TCR platform uses engineered T cell receptors to spot disease antigens with high precision, and it underpins both oncology and infectious-disease programs. The platform had 1 approved product, KIMMTRAK, and reported 2024 revenue of $297.2 million, showing real clinical and commercial traction. That mix of precision targeting and one validated launch supports a broad pipeline, but it also keeps execution risk tied to safety, antigen selection, and trial success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple Phase I\/II programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc has 4 named programs in this peptide-HLA pipeline, with IMC-C103C and IMC-F106C both in Phase I\/II dose-escalation studies. IMC-I109V is also in clinical development, while IMC-M113V remains preclinical. That breadth lowers single-asset dependence, but 3 of 4 assets are still early stage, so execution and attrition risk remain high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision medicine design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s precision medicine design centers on matching IMC therapies to defined antigens and patient subgroups, which improves selectivity and reduces off-target immune activation. KIMMTRAK, its lead product, is limited to HLA-A*02:01 patients, a genotype found in about 40% to 50% of people of European ancestry, so biomarker screening is core to access. That makes translational data and companion diagnostics key, because the company must prove antigen expression, response depth, and safety in narrower, better-defined cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiologic manufacturing complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc depends on controlled biologic manufacturing because engineered immunotherapies need tight process control, release testing, and cold-chain handling. With only one commercial product, KIMMTRAK, reliability across clinical and commercial supply is critical, since any batch drift or temperature excursion can disrupt patients and trial timelines.\u003c\/p\u003e\n\u003cp\u003eScale-up is still hard for biologics: consistency must hold from small trial lots to full launch supply, and each lot can take weeks of production and QC. That makes manufacturing uptime, yield, and comparability a direct risk factor for revenue and pipeline execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne product raises supply concentration risk.\u003c\/li\u003e\n\u003cli\u003eBatch consistency drives release success.\u003c\/li\u003e\n\u003cli\u003eCold-chain breaks can void supply.\u003c\/li\u003e\n\u003cli\u003eManufacturing uptime protects trial continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTranslational data requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s early oncology and infectious-disease work depends on biomarker, PK\/PD, and immune-response data before larger studies can start. With 1 approved medicine, KIMMTRAK, the company still has to prove dose, safety, and target engagement in small cohorts, because weak translational signals can stop a program fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eDose escalation guides go\/no-go calls.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSafety and immune readouts must align.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eStrong translational data can speed later trials.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore’s TCR Edge: Precision Promise, Execution Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s tech edge is its TCR platform: 1 approved drug, KIMMTRAK, and 4 pipeline programs, but 3 remain early stage. Precision targeting cuts off-target risk, yet it also raises reliance on biomarker testing, antigen validation, and tight biologics manufacturing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$297.2m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed programs\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and EMA oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc depends on two key regulators, the FDA and EMA, to keep KIMMTRAK and its pipeline moving. KIMMTRAK must keep meeting strict safety, efficacy, and CMC standards, and any delay in review or inspection can slow launches, trials, and sales. With 1 approved product and a small pipeline, even a short regulatory hold can hit growth fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s oncology and infectious-disease studies must meet Good Clinical Practice rules, and first-in-human or dose-escalation trials face the tightest scrutiny. Even one protocol deviation, serious safety event, or FDA\/MHRA inspection finding can pause enrollment and force remediation; in 2025, regulators kept GCP enforcement central to trial oversight.\u003c\/p\u003e\n\u003cp\u003eThis matters because a single delay can slow data readouts, raise cash burn, and push back partnering talks. For a company still scaling its pipeline, clinical compliance is not just legal risk; it is a direct driver of valuation and funding timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and exclusivity protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech value rests on IP, and Immunocore Holdings plc depends on patents, data exclusivity, and manufacturing know-how to protect KIMMTRAK and its pipeline. In fiscal 2025, KIMMTRAK still carried most commercial weight, so weaker IP would cut pricing power and reduce partner interest fast. One lost patent can turn a durable asset into a short-lived one.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharmacovigilance obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces strict pharmacovigilance duties because KIMMTRAK is an approved biologic, so it must track and report adverse events in every market where it is sold. That matters more as the product stays commercial, because post-marketing safety reviews can trigger label changes, risk-minimization steps, or extra studies. In oncology, even small safety signals can reshape use and uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing safety reporting is mandatory\u003c\/li\u003e\n\u003cli\u003eKIMMTRAK adds post-marketing burden\u003c\/li\u003e\n\u003cli\u003eSignals can change labels or studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrivacy and data laws\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc handles sensitive patient and genomic data in clinical trials, so GDPR in the UK and EU and US health-data rules like HIPAA can directly affect trial design, storage, and vendor controls.\u003c\/p\u003e\n\u003cp\u003eUnder GDPR, fines can reach €20 million or 4% of global annual turnover, whichever is higher, so a breach could hit both cash flow and approvals.\u003c\/p\u003e\n\u003cp\u003eWeak data governance can also delay studies and damage trust with regulators, sites, and patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenomic data needs tight access controls\u003c\/li\u003e\n\u003cli\u003eGDPR fines can be 4% of turnover\u003c\/li\u003e\n\u003cli\u003eFailures can delay trials and raise costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore’s Legal Risks Could Stall Trials and Delay KIMMTRAK Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces tight legal risk from FDA, EMA, and GCP rules, so any inspection finding or protocol breach can pause trials, delay KIMMTRAK revenue, and lift cash burn. Its 2025 exposure is high because one approved product still carries most commercial weight.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR breach\u003c\/td\u003e\n\u003ctd\u003eUp to €20 million or 4% of turnover\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety reporting\u003c\/td\u003e\n\u003ctd\u003eMandatory for KIMMTRAK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial compliance\u003c\/td\u003e\n\u003ctd\u003eGCP breaches can halt enrollment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiologic medicines like KIMMTRAK need tight cold-chain control, usually 2°C to 8°C, from fill-finish to patient site. Any break in temperature control can waste doses, delay trials, and disrupt delivery to treatment centers. For Immunocore Holdings plc, reliable logistics matters because clinical trial materials and commercial stock both depend on steady storage and transport.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy-intensive lab operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s expanding pipeline means more assay runs, cold storage, and clean-room time, which lifts electricity and water use at research and manufacturing sites. Biotech labs often use 3-10x the energy of standard offices, so even small efficiency gains can matter. Lower HVAC, freezer, and water loads can cut costs and help ESG targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological waste management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical and lab work at Immunocore Holdings plc produces biohazardous waste, solvents, and single-use consumables, so strict segregation and approved disposal are needed. The WHO says about 15% of healthcare waste is hazardous, which shows why mis-sorting matters. Poor handling can trigger spill incidents, fines, and higher disposal and compliance costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate-related supply disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExtreme weather can disrupt freight, power, and supplier continuity, which is risky for Immunocore Holdings plc because specialty reagents, clinical sites, and patient shipments are time-sensitive. In 2024, the U.S. had 27 billion-dollar weather disasters, showing how often logistics shocks can hit. More resilient sourcing, safety stock, and dual-site planning lower interruption risk.\u003c\/p\u003e\n\u003cp\u003eCold-chain and on-time delivery matter most when a shipment delay can stop a trial visit or spoil a reagent batch. This makes inventory buffers and backup carriers a direct risk control, not just a cost choice.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFreight delays can halt clinical supply flow\u003c\/li\u003e\n\u003cli\u003eUtility outages can affect lab operations\u003c\/li\u003e\n\u003cli\u003eDual sourcing cuts single-point failure risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG reporting pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eESG reporting pressure is rising for Immunocore Holdings plc as UK and EU rules push clearer disclosure on carbon, waste, and governance. The EU Corporate Sustainability Reporting Directive will cover about 50,000 companies, so investors and partners now compare sustainability data with pipeline progress. Strong reporting can support trust and access to capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCarbon, waste, governance now matter to investors\u003c\/li\u003e\n\u003cli\u003eCSRD expands disclosure expectations sharply\u003c\/li\u003e\n\u003cli\u003eBetter reporting can aid funding access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore’s ESG Risk: Energy, Waste, and Supply Chain Vulnerability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc depends on cold-chain control, stable power, and low-waste lab operations, so weather, outages, and transport breaks can hit trials and supply. Biotech labs often use 3-10x the energy of standard offices, and the WHO says about 15% of healthcare waste is hazardous. ESG rules are also getting tougher, with the EU CSRD covering about 50,000 companies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy use\u003c\/td\u003e\n\u003ctd\u003e3-10x office levels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous waste\u003c\/td\u003e\n\u003ctd\u003eAbout 15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSRD scope\u003c\/td\u003e\n\u003ctd\u003eAbout 50,000 firms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234564481289,"sku":"imcr-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/imcr-pestle-analysis.webp?v=1785721793","url":"https:\/\/dcfanalyst.com\/products\/imcr-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}